StudyRareStudyRare

Hutchinson-Gilford progeria

Log in to star

Last updated Nov 3, 2026

Log in to add personal notes on this page.

A 5-year-old has severe growth failure, alopecia, and aged appearance with thin skin and prominent veins. Cardiac workup reveals severe atherosclerosis.

AD, almost always de novo; LMNA, encoding lamin A. The classic variant c.1824C>T (p.Gly608Gly) activates a cryptic splice site and makes progerin, a gain of abnormal function.

Lamin A is a major component of the nuclear lamina, a protein layer attached to the inner nuclear membrane. It is made as prelamin A and farnesylated at its C-terminal CAAX box; the farnesyl tail directs it to the inner nuclear membrane, and the protease ZMPSTE24 then cuts the tail off so mature lamin A moves freely in the nuclear scaffold.

The classic variant is silent but activates a cryptic splice site in exon 11, and the protein loses 50 amino acids near its end, including the ZMPSTE24 cleavage site and the phosphorylation sites involved in dissociation and reassociation of the nuclear membrane at each cell division. Progerin stays farnesylated and likely remains bound to the inner nuclear membrane, doing progressively more damage with each mitosis. This gain of abnormal function is why one copy is enough.

Cell and mouse models with non-farnesylated progerin implicate the retained farnesyl group. Lonafarnib, a farnesyltransferase inhibitor that targets this step, extends average life span from 14.5 to about 18.7 years. Nonclassic variants that strengthen the cryptic exon 11 site or weaken the intron 11 splice donor (c.1968 and c.1968+1 to +5) also produce progerin, ranging from neonatal progeria to very mild disease.

  • Premature aging phenotype (onset ~1-2 years)
  • Severe growth failure, alopecia, loss of subcutaneous fat
  • "Aged" appearance: thin skin, prominent veins, pinched nose
  • Accelerated atherosclerosis
  • Death typically by teens (cardiovascular disease)
  • Clinical recognition of the progeroid phenotype in early childhood
  • Confirm with targeted LMNA testing for the recurrent de novo c.1824C>T (p.Gly608Gly) variant; sequencing if negative
  • Baseline cardiovascular and cerebrovascular evaluation (echocardiography, vascular imaging) given accelerated atherosclerosis
  • Lonafarnib (farnesyltransferase inhibitor) reduces progerin toxicity and prolongs survival
  • Cardiovascular surveillance and risk reduction (low-dose aspirin, statin, antiplatelet therapy) for stroke/myocardial infarction
  • Multidisciplinary supportive care: nutrition, physical therapy, skin and joint care, dental and orthopedic monitoring
  • Genetic counseling: nearly all cases are de novo; recurrence risk is low but parental gonadal mosaicism is possible

"The iLLuMiNAti are an old, secret society": The LMNA gene is hidden in "iLLMNAti", and the Illuminati are an old, secret society, linking to premature aging and the de novo (secretive) nature of the variant. Lamins are intermediate fiLAMENt proteins.

Reference Links